Radiopharmaceutical Theranostics CDMO Industry to Reach USD 5.37 Billion by 2034 as Radioligand Therapy and Nuclear Medicine Outsourcing Expand

According to a new report published by OG Analysis, the Radiopharmaceutical Theranostics CDMO Market is valued at USD 1.55 billion in 2026 and is projected to reach USD 5.37 billion by 2034, expanding at a CAGR of 16.8%. Demand is being supported by expanding radioligand therapy pipelines, companion diagnostics, personalized nuclear medicine, specialized isotope-handling requirements and growing outsourcing of complex radiopharmaceutical development and manufacturing.

Market Overview

Radiopharmaceutical theranostics CDMOs provide specialized development, manufacturing and supply-chain services for diagnostic and therapeutic radiopharmaceutical programs. Services span isotope supply support, process development, radiolabeling and conjugation, GMP drug substance and drug product manufacturing, sterile fill-finish, QC and release testing, stability studies, CMC support, packaging and radioactive logistics. Market development is accelerating as targeted radioligand therapies and companion imaging agents move deeper into oncology pipelines. Sponsors increasingly rely on external partners because radiopharmaceutical manufacturing requires capital-intensive hot-cell infrastructure, radiation-safety systems, isotope expertise, aseptic controls and rapid execution for short half-life products. Key challenges include isotope availability, transport compliance, GMP validation, sterility assurance, skilled-labor shortages, batch-release timing and capacity bottlenecks.

Key Market Insights

●      The global market is valued at USD 1.55 billion in 2026 and is forecast to reach USD 5.37 billion by 2034, representing a CAGR of 16.8% over the forecast period.

●      GMP Drug Product Manufacturing leads the service-type segment with a 26% share in 2026, supported by increasing outsourcing of compliant clinical and commercial-scale radiopharmaceutical manufacturing.

●      Lutetium-177 leads radioisotope demand with a 41% share, reflecting its expanding role in targeted radioligand therapy and theranostic oncology programs.

●      North America leads the market with a 48% share in 2026, supported by advanced GMP radiopharmaceutical infrastructure, strong clinical pipelines, isotope availability, nuclear pharmacy networks and expanding CDMO capacity.

●      Therapeutic Radiopharmaceuticals account for 38% of application/modality demand, supported by rapid growth in targeted radioligand therapies, oncology theranostics and outsourced therapeutic isotope manufacturing.

Market Dynamics

●      Rapid expansion of targeted radioligand therapy pipelines is increasing demand for specialist CDMO capacity capable of supporting radioactive drug development from early clinical programs through commercial manufacturing.

●      Biopharma companies are increasingly outsourcing radiopharmaceutical development because dedicated hot cells, radiation-safety controls, specialized personnel and isotope-handling infrastructure require significant capital investment and technical expertise.

●      Reliable isotope sourcing is becoming a major competitive differentiator as developers seek partners with secure Lutetium-177, Actinium-225, Lead-212/203, copper, gallium, fluorine and iodine supply arrangements.

●      Investment in radiolabeling, conjugation, sterile fill-finish, QC release testing and multi-isotope manufacturing infrastructure is expanding the range of clinical and commercial programs CDMOs can support.

●      Short half-lives and decay-sensitive supply chains are increasing the importance of regional manufacturing hubs, rapid batch release, validated radioactive logistics and proximity to nuclear pharmacy and treatment networks.

●      Regulatory requirements covering GMP compliance, radiation safety, aseptic processing, sterility, batch documentation and radioactive transport are strengthening demand for experienced end-to-end development and manufacturing partners.

●      Market growth is constrained by limited isotope availability, high infrastructure costs, radioactive shipment restrictions, specialized workforce shortages and the complexity of scaling short half-life products while maintaining consistent quality and supply.

Browse for More Information

https://www.oganalysis.com/industry-reports/radiopharmaceutical-theranostics-cdmo-market

Market Segmentation

The market is segmented By Service Type into Isotope Supply Support, Process Development, Radiolabeling / Conjugation, GMP Drug Substance Manufacturing, GMP Drug Product Manufacturing, Sterile Fill-Finish, QC & Release Testing, Stability Testing, CMC Support, Packaging & Radioactive Logistics; By Radioisotope Type into Lutetium-177, Actinium-225, Lead-212 / Lead-203, Gallium-68, Fluorine-18, Copper-64 / Copper-67, Iodine-131, Zirconium-89, Indium-111 and Others; and By Application / Modality into Therapeutic Radiopharmaceuticals, Diagnostic Imaging Agents, Paired Theranostic Programs, Clinical Trial Supply, Commercial Manufacturing, Oncology Radioligand Therapy, Companion Diagnostics and Personalized Nuclear Medicine. Geographic coverage includes North America, Europe, Asia-Pacific, the Middle East and Africa, and South and Central America.

Regional Insights

●      North America leads the market with a 48% share in 2026, supported by advanced radiopharmaceutical R&D, expanding radioligand therapy pipelines, established nuclear pharmacy networks, isotope availability and growing investment in specialized GMP manufacturing capacity.

●      Europe remains a major market, supported by established radiochemistry expertise, isotope production capabilities, European GMP infrastructure and strong nuclear medicine activity across Germany, Belgium and other regional markets.

●      Asia-Pacific is the fastest-growing region as capabilities in radiopharmaceutical development, isotope supply, nuclear medicine infrastructure, clinical research and specialized CDMO services continue to expand.

●      Middle East & Africa and South & Central America represent developing opportunities as nuclear medicine access, oncology infrastructure, diagnostic imaging capacity and regional radiopharmaceutical supply networks gradually expand.

Competitive Landscape

Competition is shaped by isotope access, GMP manufacturing capacity, hot-cell infrastructure, multi-isotope capability, aseptic processing, QC and release speed, regulatory expertise and radioactive logistics. Nuclear pharmacy networks, isotope suppliers, specialist radiopharma CDMOs and vertically integrated theranostics companies compete through capacity expansion, isotope partnerships, regional manufacturing hubs, acquisitions and end-to-end CMC support. As clinical pipelines advance, reliable supply and the ability to scale products from development to commercialization are becoming increasingly important differentiators.

Key companies analysed include Cardinal Health, Curium, ITM Isotope Technologies Munich, Jubilant Radiopharma, SpectronRx, Evergreen Theragnostics / Lantheus, Nucleus RadioPharma, RadioMedix, NorthStar Medical Radioisotopes, PharmaLogic / Agilera, SOFIE, AtomVie Global Radiopharma, BWXT Medical, Eckert & Ziegler, Telix Pharmaceuticals, Nusano, Isotopia Molecular Imaging, Advanced Accelerator Applications / Novartis, Medi-Radiopharma, Minerva Imaging, FutureChem, Theragnostics Ltd, ARTBIO, Alpha-9 Oncology, Fusion Pharmaceuticals / AstraZeneca, RayzeBio / Bristol Myers Squibb, POINT Biopharma / Eli Lilly, Curadh MTR, Ratio Therapeutics and AdvanCell.

Recent Developments

●      July 2026 - TD2 Oncology partnered with Minerva Imaging to provide integrated radiopharmaceutical development support, combining clinical and regulatory capabilities with radiochemistry, molecular imaging, CDMO manufacturing and radioligand-therapy expertise to help sponsors advance programs toward first-in-human trials.

●      June 2026 - Nucleus RadioPharma formed a strategic alliance with Thermo Fisher Scientific to support radiopharmaceutical developers from development through clinical execution, combining specialized manufacturing, regulatory, clinical and operational capabilities for targeted radiopharmaceutical therapies.

●      May 2026 - Minerva Imaging and Debiopharm partnered on next-generation radiopharmaceutical conjugation technology, integrating Debiopharm's AbYlink platform into Minerva's preclinical and radiopharmaceutical-development capabilities for antibody-based theranostics and other targeted formats.

●      April 2026 - Clarity Pharmaceuticals signed a commercial manufacturing agreement with Nucleus RadioPharma for Cu-64 SAR-bisPSMA, initially using Nucleus' Rochester, Minnesota facility with planned future capacity from its Pennsylvania site.

●      April 2026 - Radiopharm Theranostics signed a clinical supply agreement with Siemens Healthineers for RAD101 in the United States, with Siemens supporting radiolabeling and distribution of the F-18 diagnostic candidate for planned Phase 3 clinical development.